Recursion Pharmaceuticals Inc [NASDAQ: RXRX] gained 5.79% on the last trading session, reaching $13.15 price per share at the time. The company report on January 24, 2024 at 9:00 AM that Altitude Lab Startups Raise Over $120M in Capital.
Launches Fellowship Grant Opportunity for Early Career Entrepreneurs.
If compared to the average trading volume of 5.60M shares, RXRX reached a trading volume of 16628140 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Recursion Pharmaceuticals Inc [RXRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RXRX shares is $12.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RXRX stock is a recommendation set at 2.43. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Recursion Pharmaceuticals Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on May 22, 2023.
The Average True Range (ATR) for Recursion Pharmaceuticals Inc is set at 1.00, with the Price to Sales ratio for RXRX stock in the period of the last 12 months amounting to 59.94. The Price to Book ratio for the last quarter was 6.47, with the Price to Cash per share for the same quarter was set at 1.80.
Trading performance analysis for RXRX stock
Recursion Pharmaceuticals Inc [RXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 30.33. With this latest performance, RXRX shares gained by 32.96% in over the last four-week period, additionally plugging by 49.77% over the last 6 months – not to mention a rise of 55.81% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RXRX stock in for the last two-week period is set at 66.61, with the RSI for the last a single of trading hit 71.92, and the three-weeks RSI is set at 63.66 for Recursion Pharmaceuticals Inc [RXRX]. The present Moving Average for the last 50 days of trading for this stock 10.11, while it was recorded at 11.45 for the last single week of trading, and 8.69 for the last 200 days.
Recursion Pharmaceuticals Inc [RXRX]: A deeper dive into fundamental analysis
Recursion Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.28 and a Current Ratio set at 4.28.
Recursion Pharmaceuticals Inc [RXRX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Recursion Pharmaceuticals Inc posted -0.31/share EPS, while the average EPS was predicted by analysts to be reported at -0.29/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -6.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RXRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Recursion Pharmaceuticals Inc go to 12.00%.
An analysis of Institutional ownership at Recursion Pharmaceuticals Inc [RXRX]
The top three institutional holders of RXRX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in RXRX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in RXRX stock with ownership which is approximately 5.8325%.
